PARIS — The interventional cardiology community descends upon Paris this week for EuroPCR, a 4-day whirlwind of scientific sessions beginning Tuesday.
Kicking off the late-breaking trials are results of a LEADERS FREE substudy. The investigators previously showed that the biolimus-eluting BioFreedom stent cut rates of clinically-driven target lesion revascularization in half when compared with bare metal stents. Will the results now hold up in the subgroup of acute coronary syndrome patients? This group, after all, is “clinically very relevant,” said Stephan Windecker, MD, of Bern University Hospital in Switzerland.
Windecker, who is one of the course directors of EuroPCR, told MedPage Today that several other late-breaking trials will also be of particular interest:
TAVR: The 10-year data are finally here to “address the concern of long-term durability” of transcatheter aortic valve replacement (TAVR), according to Windecker. Outcomes were tracked in patients who got TAVR before the recent wave of improved operator experience and patient selection.
EWOLUTION: This registry study counts more than 1,000 participants who had left atrial appendage closure for stroke prevention and were at moderate-to-high risk of bleeding. The periprocedural results looked promising; and with the 3-month numbers presented at EuroPCR, clinicians may get more answers for appropriate anticoagulation and the effect of residual leakage with use of the Watchman device.
Transcatheter mitral valve implantation: Intervening in calcified native mitral valves: does it work? Windecker suggested that a global registry study may provide answers to help alleviate an “unmet need” for patients at high risk for surgery or those who are otherwise inoperable.
Featured investigations at EuroPCR are grouped by topic. On deck are sessions on peripheral interventions, percutaneous coronary intervention for diabetic patients and the very elderly, TAVR in the real world, bioresorbable scaffolds, cardiovascular imaging, and more.
EuroPCR winds up Friday, May 20.